Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free CSBR Stock Alerts

Champions Oncology (CSBR) Competitors

Champions Oncology logo
$5.98 +0.01 (+0.17%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$5.91 -0.07 (-1.15%)
As of 05/6/2026 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CSBR vs. SIGA, ORGO, CBIO, TARA, and NERV

Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Siga Technologies (SIGA), Organogenesis (ORGO), Crescent Biopharma (CBIO), Protara Therapeutics (TARA), and Minerva Neurosciences (NERV). These companies are all part of the "med - drugs" industry.

How does Champions Oncology compare to Siga Technologies?

Champions Oncology (NASDAQ:CSBR) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Siga Technologies had 2 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Siga Technologies and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.40 beat Siga Technologies' score of 0.67 indicating that Champions Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Champions Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 2.0% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Siga Technologies has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.46$4.70M-$0.16N/A
Siga Technologies$94.57M3.56$23.28M$0.3115.16

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Siga Technologies has a net margin of 24.61% compared to Champions Oncology's net margin of -3.94%. Siga Technologies' return on equity of 11.25% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
Siga Technologies 24.61%11.25%9.98%

Champions Oncology has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Summary

Siga Technologies beats Champions Oncology on 11 of the 13 factors compared between the two stocks.

How does Champions Oncology compare to Organogenesis?

Champions Oncology (NASDAQ:CSBR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Organogenesis had 2 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Organogenesis and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.40 beat Organogenesis' score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Champions Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organogenesis
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Organogenesis has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.46$4.70M-$0.16N/A
Organogenesis$564.17M0.58$37.03M$0.0832.00

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 33.0% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Organogenesis has a consensus target price of $8.50, suggesting a potential upside of 232.03%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts clearly believe Organogenesis is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Organogenesis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Organogenesis has a net margin of 5.32% compared to Champions Oncology's net margin of -3.94%. Organogenesis' return on equity of 21.41% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
Organogenesis 5.32%21.41%10.84%

Champions Oncology has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Summary

Organogenesis beats Champions Oncology on 13 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Crescent Biopharma?

Champions Oncology (NASDAQ:CSBR) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Crescent Biopharma had 15 more articles in the media than Champions Oncology. MarketBeat recorded 16 mentions for Crescent Biopharma and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.40 beat Crescent Biopharma's score of 0.30 indicating that Champions Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Champions Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Crescent Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Champions Oncology has higher revenue and earnings than Crescent Biopharma. Champions Oncology is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.46$4.70M-$0.16N/A
Crescent Biopharma$10.84M45.92-$153.94M-$10.91N/A

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Crescent Biopharma has a consensus target price of $28.00, suggesting a potential upside of 55.04%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Crescent Biopharma is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Crescent Biopharma
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
3 Strong Buy rating(s)
3.11

Crescent Biopharma has a net margin of 0.00% compared to Champions Oncology's net margin of -3.94%. Champions Oncology's return on equity of -57.31% beat Crescent Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
Crescent Biopharma N/A -103.44%-88.19%

Champions Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Summary

Crescent Biopharma beats Champions Oncology on 10 of the 17 factors compared between the two stocks.

How does Champions Oncology compare to Protara Therapeutics?

Champions Oncology (NASDAQ:CSBR) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Protara Therapeutics had 4 more articles in the media than Champions Oncology. MarketBeat recorded 5 mentions for Protara Therapeutics and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.40 beat Protara Therapeutics' score of 0.87 indicating that Champions Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Champions Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protara Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 8.4% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Champions Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Protara Therapeutics has a net margin of 0.00% compared to Champions Oncology's net margin of -3.94%. Protara Therapeutics' return on equity of -36.38% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
Protara Therapeutics N/A -36.38%-33.81%

Champions Oncology has higher revenue and earnings than Protara Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.46$4.70M-$0.16N/A
Protara TherapeuticsN/AN/A-$57.44M-$1.32N/A

Protara Therapeutics has a consensus target price of $24.75, suggesting a potential upside of 337.28%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

Protara Therapeutics beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Minerva Neurosciences?

Champions Oncology (NASDAQ:CSBR) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 47.0% of Champions Oncology shares are owned by insiders. Comparatively, 10.4% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Champions Oncology has higher revenue and earnings than Minerva Neurosciences. Champions Oncology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.46$4.70M-$0.16N/A
Minerva NeurosciencesN/AN/A-$293.42M-$26.80N/A

Champions Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500.

Minerva Neurosciences has a net margin of 0.00% compared to Champions Oncology's net margin of -3.94%. Minerva Neurosciences' return on equity of 0.00% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
Minerva Neurosciences N/A N/A -39.18%

Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 68.54%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Minerva Neurosciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Minerva Neurosciences had 4 more articles in the media than Champions Oncology. MarketBeat recorded 5 mentions for Minerva Neurosciences and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.40 beat Minerva Neurosciences' score of -0.07 indicating that Champions Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Champions Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Minerva Neurosciences
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Champions Oncology beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSBR vs. The Competition

Export
MetricChampions OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$82.90M$3.11B$6.28B$11.90B
Dividend YieldN/A1.89%2.77%5.26%
P/E Ratio-37.3818.5229.1527.34
Price / Sales1.46312.38494.4986.04
Price / Cash13.0256.0143.4254.56
Price / Book22.154.369.846.79
Net Income$4.70M$72.19M$3.55B$332.68M
7 Day Performance0.34%3.06%2.24%2.55%
1 Month Performance-2.91%7.96%6.39%9.36%
1 Year Performance3.28%51.72%44.80%45.22%

Champions Oncology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CSBR
Champions Oncology
0.2968 of 5 stars		$5.98
+0.2%		N/A+2.0%$82.90M$56.94MN/A143
SIGA
Siga Technologies
1.4258 of 5 stars		$4.53
-1.3%		N/A-10.8%$324.55M$94.57M14.6140
ORGO
Organogenesis
3.1024 of 5 stars		$2.30
-4.2%		$8.50
+269.6%		-50.8%$295.87M$563.03M28.75950
CBIO
Crescent Biopharma
2.2833 of 5 stars		$20.94
-12.6%		$28.00
+33.7%		N/A$290.92M$10.84MN/A50
TARA
Protara Therapeutics
2.6257 of 5 stars		$5.17
+2.2%		$24.75
+378.7%		+68.0%$284.67MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel